A PHASE IV MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE THERAPY IN CHINESE PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC)

被引：0
|
作者：
Qin, S. [1 ]
Jin, J. [2 ]
Guo, J. [3 ]
Wang, J. [4 ,5 ]
Zhou, F. [6 ]
Huang, Y. [7 ]
Ren, X. [8 ]
Ye, D. [9 ]
Wang, Q. [10 ]
Pan, S. [11 ]
机构：
[1] Nanjing Bayi Hosp, Pla Canc Ctr, Nanjing, Peoples R China
[2] Peking Univ First Hosp, Beijing, Peoples R China
[3] Peking Univ Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[4] Peking Union Med Coll, Canc Hosp Inst, Beijing 100021, Peoples R China
[5] Chinese Acad Med Sci, Beijing 100730, Peoples R China
[6] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
[7] Shanghai Renji Hosp, Shanghai, Peoples R China
[8] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[9] Fudan Univ Shanghai Canc Ctr, Shanghai, Peoples R China
[10] Pfizer, Global Res & Dev, Shanghai, Peoples R China
[11] Pfizer, Clin Stat, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：282 / 282
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of first-line sunitinib in Chinese patients with metastatic renal cell carcinoma
    Qin, Shu-Kui
    Jin, Jie
    Guo, Jun
    Wang, Jin-Wan
    Zhou, Fang-Dian
    Huang, Yi-Ran
    Ren, Xiu-Bao
    Ye, Ding-Wei
    Pan, Sharon
    Sajben, Peter
    Wang, Qiao
    [J]. FUTURE ONCOLOGY, 2018, 14 (18) : 1835 - 1845
  • [2] Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Ernst, D. Scott
    Canil, Christina M.
    Winquist, Eric
    Zalewski, Pawel
    Hotte, Sebastien J.
    North, Scott A.
    Heng, Daniel Yick Chin
    Macfarlane, Robyn Jane
    Venner, Peter M.
    Tannock, Ian
    Kapoor, Anil
    Eigl, Bernhard J.
    Hansen, Aaron Richard
    Czaykowski, Piotr
    Boyd, Ben
    Basappa, Naveen S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma (mRCC)
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Comparison of efficacy, safety,and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
    Wen Cai
    Wen Kong
    Baijun Dong
    Jin Zhang
    Yonghui Chen
    Wei Xue
    Yiran Huang
    Lixin Zhou
    Jiwei Huang
    [J]. 癌症, 2017, 36 (11) : 574 - 582
  • [5] Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma
    Cai, Wen
    Kong, Wen
    Dong, Baijun
    Zhang, Jin
    Chen, Yonghui
    Xue, Wei
    Huang, Yiran
    Zhou, Lixin
    Huang, Jiwei
    [J]. CHINESE JOURNAL OF CANCER, 2017, 36
  • [6] EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW
    Huerfano, C.
    NinoNino, C. P.
    Davila, F.
    Reyes, J. M.
    Diaz, J. A.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A169 - A169
  • [7] A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Reaume, M. Neil Neil
    Lalewski, Pawel
    Macfarlane, Robyn Jane
    MacKenzie, Mary J.
    Hotte, Sebastien J.
    Heng, Daniel Vick Chin
    Soulieres, Denis
    Miller, Jessie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [9] The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Ernst, D. Scott
    Zalewski, Pawel
    Canil, Christina M.
    Winquist, Eric
    Hotte, Sebastien J.
    North, Scott A.
    Heng, Daniel Yick Chin
    Macfarlane, Robyn Jane
    Venner, Peter M.
    Kapoor, Anil
    Hansen, Aaron R.
    Eigl, Bernhard J.
    Czaykowski, Piotr
    Boyd, Ben
    Wang, Lisa
    Basappa, Naveen S.
    [J]. EUROPEAN JOURNAL OF CANCER, 2019, 108 : 69 - 77
  • [10] Safety and efficacy of tivozanib in first-line metastatic renal cell carcinoma: A multicenter compassionate use study
    Basso, Umberto
    Procopio, Giuseppe
    Fornarini, Giuseppe
    Massari, Francesco
    Bearz, Alessandra
    Fratino, Lucia
    Milella, Michele
    Bassanelli, Maria
    Sacco, Cosimo
    Bimbatti, Davide
    Verzoni, Elena
    Rizzo, Mimma
    Porta, Camillo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345